Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 4.09
(1.11%)
SEK 4.09
(1.11%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 103.4 Million SEK | 9300.0% |
| 2022 | 1.1 Million SEK | -58.49% |
| 2021 | 2.65 Million SEK | -24.84% |
| 2020 | 3.52 Million SEK | 2913.68% |
| 2019 | 117 Thousand SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| 2008 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 105 Million SEK | 1.55% |
| 2024 Q2 | 89.4 Million SEK | -14.86% |
| 2023 Q1 | 3.8 Million SEK | 245.45% |
| 2023 Q3 | 2.7 Million SEK | -18.18% |
| 2023 Q2 | 3.3 Million SEK | -13.16% |
| 2023 Q4 | 103.4 Million SEK | 3729.63% |
| 2023 FY | 103.4 Million SEK | 9300.0% |
| 2022 Q3 | 1.5 Million SEK | -20.09% |
| 2022 FY | 1.1 Million SEK | -58.49% |
| 2022 Q4 | 1.1 Million SEK | -26.67% |
| 2022 Q1 | 2.26 Million SEK | -14.53% |
| 2022 Q2 | 1.87 Million SEK | -17.13% |
| 2021 Q1 | 3.22 Million SEK | -8.65% |
| 2021 Q3 | 2.9 Million SEK | -14.78% |
| 2021 FY | 2.65 Million SEK | -24.84% |
| 2021 Q4 | 2.65 Million SEK | -8.78% |
| 2021 Q2 | 3.4 Million SEK | 5.84% |
| 2020 FY | 3.52 Million SEK | 2913.68% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | 3.52 Million SEK | 0.0% |
| 2020 Q2 | - SEK | -100.0% |
| 2020 Q1 | 29 Thousand SEK | -75.21% |
| 2019 Q1 | 117 Thousand SEK | 0.0% |
| 2019 FY | 117 Thousand SEK | 0.0% |
| 2019 Q4 | 117 Thousand SEK | 0.0% |
| 2019 Q3 | 117 Thousand SEK | 0.0% |
| 2019 Q2 | 117 Thousand SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| 2008 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 939.5 Million SEK | 88.994% |
| Camurus AB (publ) | 13.61 Million SEK | -659.568% |
| Mendus AB (publ) | 850 Thousand SEK | -12064.706% |
| Lipum AB (publ) | 1.76 Million SEK | -5771.664% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | -13.952% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | 3 Million SEK | -3346.667% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -10240.0% |
| BioArctic AB (publ) | 2.15 Million SEK | -4704.833% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -237.115% |
| Genovis AB (publ.) | 74.8 Million SEK | -38.221% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| Intervacc AB (publ) | 142 Thousand SEK | -72716.901% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 32.58 Million SEK | -217.353% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 65.23 Million SEK | -58.497% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Xbrane Biopharma AB (publ) | 112.89 Million SEK | 8.412% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 31.94 Million SEK | -223.661% |
| Ziccum AB (publ) | 286 Thousand SEK | -36053.846% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| Alligator Bioscience AB (publ) | 7.51 Million SEK | -1275.732% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 24.51 Million SEK | -321.851% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 4.29 Million SEK | -2306.89% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -24286.792% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 844.9 Million SEK | 87.762% |
| Cyxone AB (publ) | 74 Thousand SEK | -139629.73% |
| ExpreS2ion Biotech Holding AB (publ) | 1.43 Million SEK | -7100.557% |
| Biosergen AB | - SEK | -Infinity% |
| Nanologica AB (publ) | 136 Thousand SEK | -75929.412% |
| SynAct Pharma AB | 58 Thousand SEK | -178175.862% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 14.53 Million SEK | -611.386% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -12064.706% |
| Alzinova AB (publ) | 800 Thousand SEK | -12825.0% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 2.899% |
| Pila Pharma AB (publ) | - SEK | -Infinity% |
| Ascelia Pharma AB (publ) | 176 Thousand SEK | -58650.0% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |